Bone morphogenetic proteins and their antagonists: Current and emerging clinical uses

British Journal of Pharmacology

Volumn 171, Issue 15, 2014, Pages 3620-3632

  Ali, Imran H A ^a   Brazil, Derek P ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

bone morphogenetic protein; fibrosis; fracture; gremlin; inhibitors; scarring; skeleton

Indexed keywords

BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; BONE MORPHOGENETIC PROTEIN RECEPTOR 1; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; COLLAGEN SPONGE; INFUSE; OSTEOGENIC PROTEIN 1; PARVOVIRUS VECTOR; PLACEBO; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; RECOMBINANT OSTEOGENIC PROTEIN 1; SMAD1 PROTEIN; SMAD5 PROTEIN; SMAD8 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; RECOMBINANT PROTEIN; SMAD PROTEIN;

BONE DEVELOPMENT; BONE GRAFT; BONE REMODELING; CARBON TETRACHLORIDE-INDUCED LIVER FIBROSIS; CHONDROGENESIS; COLITIS; CYTOKINE RELEASE; DIABETIC NEPHROPATHY; DRUG COST; EPITHELIAL MESENCHYMAL TRANSITION; FRACTURE HEALING; FRACTURE NONUNION; HEART MUSCLE FIBROSIS; HEMATOMA; HUMAN; INFLAMMATORY BOWEL DISEASE; KIDNEY FIBROSIS; KNEE OSTEOARTHRITIS; LIVER FIBROSIS; NEUROLOGIC DISEASE; NONHUMAN; OFF LABEL DRUG USE; OPEN FRACTURE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RETROGRADE EJACULATION; REVIEW; SIGNAL TRANSDUCTION; SPINE FUSION; SWELLING; TIBIA FRACTURE; ANIMAL; ANTAGONISTS AND INHIBITORS; BONE REGENERATION; DRUG EFFECTS; FIBROSIS; METABOLISM;

ANIMALS; BONE DEVELOPMENT; BONE MORPHOGENETIC PROTEINS; BONE REGENERATION; FIBROSIS; HUMANS; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; SMAD PROTEINS;

EID: 84904567021     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12724     Document Type: Review

References (158)

1. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, Peters JA, Harmar AJ, and CGTP Collaborators (2013). The Concise Guide to PHARMACOLOGY 2013/14:Catalytic receptors. Br J Pharmacol 170: 1676-1705.
2. Aoki H, Fujii M, Imamura T, Yagi K, Takehara K, Kato M, etal. (2001). Synergistic effects of different bone morphogenetic protein type I receptors on alkaline phosphatase induction. J Cell Sci 114 (Pt 8): 1483-1489.
3. Balemans W, Van Hul W, (2002). Extracellular regulation of BMP signaling in vertebrates: a cocktail of modulators. Dev Biol 250: 231-250.
4. Boerckel JD, Kolambkar YM, Dupont KM, Uhrig BA, Phelps EA, Stevens HY, etal. (2011). Effects of protein dose and delivery system on BMP-mediated bone regeneration. Biomaterials 32: 5241-5251.
5. Boergermann JH, Kopf J, Yu PB, Knaus P, (2010). Dorsomorphin and LDN-193189 inhibit BMP-mediated Smad, p38 and Akt signalling in C2C12 cells. Int J Biochem Cell Biol 42: 1802-1807.
6. Bohle A, Strutz F, Muller GA, (1994). On the pathogenesis of chronic renal failure in primary glomerulopathies: a view from the interstitium. Exp Nephrol 2: 205-210.
7. Boon MR, van der Horst G, van der Pluijm G, Tamsma JT, Smit JW, Rensen PC, (2011). Bone morphogenetic protein 7: a broad-spectrum growth factor with multiple target therapeutic potency. Cytokine Growth Factor Rev 22: 221-229.
8. Bragdon B, Moseychuk O, Saldanha S, King D, Julian J, Nohe A, (2011). Bone morphogenetic proteins: a critical review. Cell Signal 23: 609-620.
9. Brunkow ME, Gardner JC, Van Ness J, Paeper BW, Kovacevich BR, Proll S, etal. (2001). Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet 68: 577-589.
10. Cahill E, Costello CM, Rowan SC, Harkin S, Howell K, Leonard MO, etal. (2012). Gremlin plays a key role in the pathogenesis of pulmonary hypertension. Circulation 125: 920-930.
11. Carvajal G, Droguett A, Burgos ME, Aros C, Ardiles L, Flores C, etal. (2008). Gremlin: a novel mediator of epithelial mesenchymal transition and fibrosis in chronic allograft nephropathy. Transplant Proc 40: 734-739.
12. Chacko BM, Qin B, Correia JJ, Lam SS, de Caestecker MP, Lin K, (2001). The L3 loop and C-terminal phosphorylation jointly define Smad protein trimerization. Nat Struct Biol 8: 248-253.
13. Chen X, Weisberg E, Fridmacher V, Watanabe M, Naco G, Whitman M, (1997). Smad4 and FAST-1 in the assembly of activin-responsive factor. Nature 389: 85-89.
14. Ciuclan L, Sheppard K, Dong L, Sutton D, Duggan N, Hussey M, etal. (2013). Treatment with anti-gremlin 1 antibody ameliorates chronic hypoxia/SU5416-induced pulmonary arterial hypertension in mice. Am J Pathol 183: 1461-1473.
15. Cook SD, Dalton JE, Tan EH, Whitecloud TS 3rd, Rueger DC, (1994). In vivo evaluation of recombinant human osteogenic protein (rhOP-1) implants as a bone graft substitute for spinal fusions. Spine 19: 1655-1663.
16. Costello CM, Howell K, Cahill E, McBryan J, Konigshoff M, Eickelberg O, etal. (2008). Lung-selective gene responses to alveolar hypoxia: potential role for the bone morphogenetic antagonist gremlin in pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 295: L272-L284.
17. Daluiski A, Engstrand T, Bahamonde ME, Gamer LW, Agius E, Stevenson SL, etal. (2001). Bone morphogenetic protein-3 is a negative regulator of bone density. Nat Genet 27: 84-88.
18. Dolan V, Murphy M, Sadlier D, Lappin D, Doran P, Godson C, etal. (2005). Expression of gremlin, a bone morphogenetic protein antagonist, in human diabetic nephropathy. Am J Kidney Dis 45: 1034-1039.
19. Dudas PL, Argentieri RL, Farrell FX, (2009). BMP-7 fails to attenuate TGF-beta1-induced epithelial-to-mesenchymal transition in human proximal tubule epithelial cells. Nephrol Dial Transplant 24: 1406-1416.
20. Einhorn TA, Majeska RJ, Mohaideen A, Kagel EM, Bouxsein ML, Turek TJ, etal. (2003). A single percutaneous injection of recombinant human bone morphogenetic protein-2 accelerates fracture repair. J Bone Joint Surg Am 85-A: 1425-1435.
21. Epstein NE, (2013). Complications due to the use of BMP/INFUSE in spine surgery: the evidence continues to mount. Surg Neurol Int 4 (Suppl. 5): S343-S352.
22. Fan Z, Chubinskaya S, Rueger DC, Bau B, Haag J, Aigner T, (2004). Regulation of anabolic and catabolic gene expression in normal and osteoarthritic adult human articular chondrocytes by osteogenic protein-1. Clin Exp Rheumatol 22: 103-106.
23. Farkas L, Farkas D, Gauldie J, Warburton D, Shi W, Kolb M, (2011). Transient overexpression of gremlin results in epithelial activation and reversible fibrosis in rat lungs. Am J Respir Cell Mol Biol 44: 870-878.
24. Gamer LW, Nove J, Levin M, Rosen V, (2005). BMP-3 is a novel inhibitor of both activin and BMP-4 signaling in Xenopus embryos. Dev Biol 285: 156-168.
25. Gamer LW, Cox K, Carlo JM, Rosen V, (2009). Overexpression of BMP3 in the developing skeleton alters endochondral bone formation resulting in spontaneous rib fractures. Dev Dyn 238: 2374-2381.
26. Garrison KR, Donell S, Ryder J, Shemilt I, Mugford M, Harvey I, etal. (2007). Clinical effectiveness and cost-effectiveness of bone morphogenetic proteins in the non-healing of fractures and spinal fusion: a systematic review. Health Technol Assess 11: 1-150, iii-iv.
27. Garrison KR, Shemilt I, Donell S, Ryder JJ, Mugford M, Harvey I, etal. (2010). Bone morphogenetic protein (BMP) for fracture healing in adults. Cochrane Database Syst Rev (6): CD006950.
28. Gautschi OP, Frey SP, Zellweger R, (2007). Bone morphogenetic proteins in clinical applications. ANZ J Surg 77: 626-631.
29. Gazzerro E, Pereira RC, Jorgetti V, Olson S, Economides AN, Canalis E, (2005). Skeletal overexpression of gremlin impairs bone formation and causes osteopenia. Endocrinology 146: 655-665.
30. Gazzerro E, Smerdel-Ramoya A, Zanotti S, Stadmeyer L, Durant D, Economides AN, etal. (2007). Conditional deletion of gremlin causes a transient increase in bone formation and bone mass. J Biol Chem 282: 31549-31557.
31. Govender S, Csimma C, Genant HK, Valentin-Opran A, Amit Y, Arbel R, etal. (2002). Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: a prospective, controlled, randomized study of four hundred and fifty patients. J Bone Joint Surg Am 84-A: 2123-2134.
32. Grgic I, Duffield JS, Humphreys BD, (2012). The origin of interstitial myofibroblasts in chronic kidney disease. Pediatr Nephrol 27: 183-193.
33. Groppe J, Greenwald J, Wiater E, Rodriguez-Leon J, Economides AN, Kwiatkowski W, etal. (2002). Structural basis of BMP signalling inhibition by the cystine knot protein Noggin. Nature 420: 636-642.
34. Guillot N, Kollins D, Gilbert V, Xavier S, Chen J, Gentle M, etal. (2012). BAMBI regulates angiogenesis and endothelial homeostasis through modulation of alternative TGFβ signaling. PLoS ONE 7: e39406.
35. Guo J, Wu G, (2012). The signaling and functions of heterodimeric bone morphogenetic proteins. Cytokine Growth Factor Rev 23: 61-67.
36. Hamada S, Satoh K, Hirota M, Kimura K, Kanno A, Masamune A, etal. (2007). Bone morphogenetic protein 4 induces epithelial-mesenchymal transition through MSX2 induction on pancreatic cancer cell line. J Cell Physiol 213: 768-774.
37. Hao ZM, Cai M, Lv YF, Huang YH, Li HH, (2012). Oral administration of recombinant adeno-associated virus-mediated bone morphogenetic protein-7 suppresses CCl(4)-induced hepatic fibrosis in mice. Mol Ther 20: 2043-2051.
38. Hata A, Lagna G, Massague J, Hemmati-Brivanlou A, (1998). Smad6 inhibits BMP/Smad1 signaling by specifically competing with the Smad4 tumor suppressor. Genes Dev 12: 186-197.
39. Horiki M, Imamura T, Okamoto M, Hayashi M, Murai J, Myoui A, etal. (2004). Smad6/Smurf1 overexpression in cartilage delays chondrocyte hypertrophy and causes dwarfism with osteopenia. J Cell Biol 165: 433-445.
40. Hsu DR, Economides AN, Wang X, Eimon PM, Harland RM, (1998). The Xenopus dorsalizing factor gremlin identifies a novel family of secreted proteins that antagonize BMP activities. Mol Cell 1: 673-683.
41. Huch K, Wilbrink B, Flechtenmacher J, Koepp HE, Aydelotte MB, Sampath TK, etal. (1997). Effects of recombinant human osteogenic protein 1 on the production of proteoglycan, prostaglandin E2, and interleukin-1 receptor antagonist by human articular chondrocytes cultured in the presence of interleukin-1beta. Arthritis Rheum 40: 2157-2161.
42. Hunter DJ, Pike MC, Jonas BL, Kissin E, Krop J, McAlindon T, (2010). Phase 1 safety and tolerability study of BMP-7 in symptomatic knee osteoarthritis. BMC Musculoskelet Disord 11: 232.
43. Im HJ, Pacione C, Chubinskaya S, Van Wijnen AJ, Sun Y, Loeser RF, (2003). Inhibitory effects of insulin-like growth factor-1 and osteogenic protein-1 on fibronectin fragment- and interleukin-1beta-stimulated matrix metalloproteinase-13 expression in human chondrocytes. J Biol Chem 278: 25386-25394.
44. Ishibashi O, Ikegame M, Takizawa F, Yoshizawa T, Moksed MA, Iizawa F, etal. (2010). Endoglin is involved in BMP-2-induced osteogenic differentiation of periodontal ligament cells through a pathway independent of Smad-1/5/8 phosphorylation. J Cell Physiol 222: 465-473.
45. Israel DI, Nove J, Kerns KM, Kaufman RJ, Rosen V, Cox KA, etal. (1996). Heterodimeric bone morphogenetic proteins show enhanced activity in vitro and in vivo. Growth Factors 13: 291-300.
46. Itoh S, Landstrom M, Hermansson A, Itoh F, Heldin CH, Heldin NE, etal. (1998). Transforming growth factor beta1 induces nuclear export of inhibitory Smad7. J Biol Chem 273: 29195-29201.
47. Iwano M, Plieth D, Danoff TM, Xue C, Okada H, Neilson EG, (2002). Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest 110: 341-350.
48. Jones AL, Bucholz RW, Bosse MJ, Mirza SK, Lyon TR, Webb LX, etal. (2006). Recombinant human BMP-2 and allograft compared with autogenous bone graft for reconstruction of diaphyseal tibial fractures with cortical defects. A randomized, controlled trial. J Bone Joint Surg Am 88: 1431-1441.
49. Kang YH, Jin JS, Yi DW, Son SM, (2010). Bone morphogenetic protein-7 inhibits vascular calcification induced by high vitamin D in mice. Tohoku J Exp Med 221: 299-307.
50. Karsenty G, (2003). The complexities of skeletal biology. Nature 423: 316-318.
51. Koepp HE, Sampath KT, Kuettner KE, Homandberg GA, (1999). Osteogenic protein-1 (OP-1) blocks cartilage damage caused by fibronectin fragments and promotes repair by enhancing proteoglycan synthesis. Inflamm Res 48: 199-204.
52. Kokabu S, Gamer L, Cox K, Lowery J, Tsuji K, Raz R, etal. (2012). BMP3 suppresses osteoblast differentiation of bone marrow stromal cells via interaction with Acvr2b. Mol Endocrinol 26: 87-94.
53. Koli K, Myllarniemi M, Vuorinen K, Salmenkivi K, Ryynanen MJ, Kinnula VL, etal. (2006). Bone morphogenetic protein-4 inhibitor gremlin is overexpressed in idiopathic pulmonary fibrosis. Am J Pathol 169: 61-71.
54. Komori T, Yagi H, Nomura S, Yamaguchi A, Sasaki K, Deguchi K, etal. (1997). Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 89: 755-764.
55. LeBleu VS, Taduri G, O'Connell J, Teng Y, Cooke VG, Woda C, etal. (2013). Origin and function of myofibroblasts in kidney fibrosis. Nat Med 19: 1047-1053.
56. Lee H, O'Meara SJ, O'Brien C, Kane R, (2007). The role of gremlin, a BMP antagonist, and epithelial-to-mesenchymal transition in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 48: 4291-4299.
57. Lehmann K, Seemann P, Silan F, Goecke TO, Irgang S, Kjaer KW, etal. (2007). A new subtype of brachydactyly type B caused by point mutations in the bone morphogenetic protein antagonist NOGGIN. Am J Hum Genet 81: 388-396.
58. Lepparanta O, Tikkanen JM, Bespalov MM, Koli K, Myllarniemi M, (2013). Bone morphogenetic protein-inducer tilorone identified by high-throughput screening is antifibrotic in vivo. Am J Respir Cell Mol Biol 48: 448-455.
59. Li W, Dunmore BJ, Morrell NW, (2010). Bone morphogenetic protein type II receptor mutations causing protein misfolding in heritable pulmonary arterial hypertension. Proc Am Thorac Soc 7: 395-398.
60. Li X, Cao X, (2006). BMP signaling and skeletogenesis. Ann N Y Acad Sci 1068: 26-40.
61. Liebergall M, Schroeder J, Mosheiff R, Gazit Z, Yoram Z, Rasooly L, etal. (2013). Stem cell-based therapy for prevention of delayed fracture union: a randomized and prospective preliminary study. Mol Ther 21: 1631-1638.
62. Lin J, Patel SR, Cheng X, Cho EA, Levitan I, Ullenbruch M, etal. (2005). Kielin/chordin-like protein, a novel enhancer of BMP signaling, attenuates renal fibrotic disease. Nat Med 11: 387-393.
63. Lin J, Patel SR, Wang M, Dressler GR, (2006a). The cysteine-rich domain protein KCP is a suppressor of transforming growth factor beta/activin signaling in renal epithelia. Mol Cell Biol 26: 4577-4585.
64. Lin X, Duan X, Liang YY, Su Y, Wrighton KH, Long J, etal. (2006b). PPM1A functions as a Smad phosphatase to terminate TGFbeta signaling. Cell 125: 915-928.
65. Liu IM, Schilling SH, Knouse KA, Choy L, Derynck R, Wang XF, (2009). TGFbeta-stimulated Smad1/5 phosphorylation requires the ALK5 L45 loop and mediates the pro-migratory TGFbeta switch. EMBO J 28: 88-98.
66. Maric I, Poljak L, Zoricic S, Bobinac D, Bosukonda D, Sampath KT, etal. (2003). Bone morphogenetic protein-7 reduces the severity of colon tissue damage and accelerates the healing of inflammatory bowel disease in rats. J Cell Physiol 196: 258-264.
67. Maric I, Kucic N, Turk Wensveen T, Smoljan I, Grahovac B, Zoricic Cvek S, etal. (2012). BMP signaling in rats with TNBS-induced colitis following BMP7 therapy. Am J Physiol Gastrointest Liver Physiol 302: G1151-G1162.
68. Massague J, Seoane J, Wotton D, (2005). Smad transcription factors. Genes Dev 19: 2783-2810.
69. McCormack N, O'Dea S, (2013). Regulation of epithelial to mesenchymal transition by bone morphogenetic proteins. Cell Signal 25: 2856-2862.
70. McCormack N, Molloy EL, O'Dea S, (2013). Bone morphogenetic proteins enhance an epithelial-mesenchymal transition in normal airway epithelial cells during restitution of a disrupted epithelium. Respir Res 14: 36.
71. Mezzano S, Droguett A, Burgos ME, Aros C, Ardiles L, Flores C, etal. (2007). Expression of gremlin, a bone morphogenetic protein antagonist, in glomerular crescents of pauci-immune glomerulonephritis. Nephrol Dial Transplant 22: 1882-1890.
72. Michos O, Goncalves A, Lopez-Rios J, Tiecke E, Naillat F, Beier K, etal. (2007). Reduction of BMP4 activity by gremlin 1 enables ureteric bud outgrowth and GDNF/WNT11 feedback signalling during kidney branching morphogenesis. Development 134: 2397-2405.
73. Mikawa S, Sato K, (2013). Chordin expression in the adult rat brain. Neuroscience 258C: 16-33.
74. Miyazono K, Kamiya Y, Morikawa M, (2010). Bone morphogenetic protein receptors and signal transduction. J Biochem 147: 35-51.
75. Molloy EL, Adams A, Moore JB, Masterson JC, Madrigal-Estebas L, Mahon BP, etal. (2008). BMP4 induces an epithelial-mesenchymal transition-like response in adult airway epithelial cells. Growth Factors 26: 12-22.
76. Mueller KA, Tavlaki E, Schneider M, Jorbenadze R, Geisler T, Kandolf R, etal. (2013). Gremlin-1 identifies fibrosis and predicts adverse outcome in patients with heart failure undergoing endomyocardial biopsy. J Card Fail 19: 678-684.
77. Murakami G, Watabe T, Takaoka K, Miyazono K, Imamura T, (2003). Cooperative inhibition of bone morphogenetic protein signaling by Smurf1 and inhibitory Smads. Mol Biol Cell 14: 2809-2817.
78. Murakami M, Kawachi H, Ogawa K, Nishino Y, Funaba M, (2009). Receptor expression modulates the specificity of transforming growth factor-beta signaling pathways. Genes Cells 14: 469-482.
79. Murray LA, Hackett TL, Warner SM, Shaheen F, Argentieri RL, Dudas P, etal. (2008). BMP-7 does not protect against bleomycin-induced lung or skin fibrosis. PLoS ONE 3: e4039.
80. Myllarniemi M, Lindholm P, Ryynanen MJ, Kliment CR, Salmenkivi K, Keski-Oja J, etal. (2008). Gremlin-mediated decrease in bone morphogenetic protein signaling promotes pulmonary fibrosis. Am J Respir Crit Care Med 177: 321-329.
81. Nakamura J, Yanagita M, (2012). Bmp modulators in kidney disease. Discov Med 13: 57-63.
82. Nauth A, Ristiniemi J, McKee MD, Schemitsch EH, (2009). Bone morphogenetic proteins in open fractures: past, present, and future. Injury 40 (Suppl. 3): S27-S31.
83. Nelsen SM, Christian JL, (2009). Site-specific cleavage of BMP4 by furin, PC6, and PC7. J Biol Chem 284: 27157-27166.
84. Nishida Y, Knudson CB, Knudson W, (2004). Osteogenic Protein-1 inhibits matrix depletion in a hyaluronan hexasaccharide-induced model of osteoarthritis. Osteoarthritis Cartilage 12: 374-382.
85. Nishimura R, Hata K, Ikeda F, Ichida F, Shimoyama A, Matsubara T, etal. (2008). Signal transduction and transcriptional regulation during mesenchymal cell differentiation. J Bone Miner Metab 26: 203-212.
86. Nishimura R, Hata K, Matsubara T, Wakabayashi M, Yoneda T, (2012). Regulation of bone and cartilage development by network between BMP signalling and transcription factors. J Biochem 151: 247-254.
87. Nohe A, Keating E, Knaus P, Petersen NO, (2004). Signal transduction of bone morphogenetic protein receptors. Cell Signal 16: 291-299.
88. Okada H, Danoff TM, Kalluri R, Neilson EG, (1997). Early role of Fsp1 in epithelial-mesenchymal transformation. Am J Physiol 273 (4 Pt 2): F563-F574.
89. Onichtchouk D, Chen YG, Dosch R, Gawantka V, Delius H, Massague J, etal. (1999). Silencing of TGF-beta signalling by the pseudoreceptor BAMBI. Nature 401: 480-485.
90. Otto F, Thornell AP, Crompton T, Denzel A, Gilmour KC, Rosewell IR, etal. (1997). Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell 89: 765-771.
91. Otto F, Kanegane H, Mundlos S, (2002). Mutations in the RUNX2 gene in patients with cleidocranial dysplasia. Hum Mutat 19: 209-216.
92. Oumi N, Taniguchi KA, Kanai AM, Yasunaga M, Nakanishi T, Sato K, (2012). A crucial role of bone morphogenetic protein signaling in the wound healing response in acute liver injury induced by carbon tetrachloride. Int J Hepatol 2012: 476820.
93. Pardali E, van der Schaft DW, Wiercinska E, Gorter A, Hogendoorn PC, Griffioen AW, etal. (2011). Critical role of endoglin in tumor cell plasticity of Ewing sarcoma and melanoma. Oncogene 30: 334-345.
94. Peinado H, Olmeda D, Cano A, (2007). Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer 7: 415-428.
95. Riggins GJ, Thiagalingam S, Rozenblum E, Weinstein CL, Kern SE, Hamilton SR, etal. (1996). Mad-related genes in the human. Nat Genet 13: 347-349.
96. Ristiniemi J, Flinkkila T, Hyvonen P, Lakovaara M, Pakarinen H, Jalovaara P, (2007). RhBMP-7 accelerates the healing in distal tibial fractures treated by external fixation. J Bone Joint Surg Br 89: 265-272.
97. Rodrigues-Diez R, Lavoz C, Carvajal G, Rayego-Mateos S, Rodrigues Diez RR, Ortiz A, etal. (2012). Gremlin is a downstream profibrotic mediator of transforming growth factor-beta in cultured renal cells. Nephron Exp Nephrol 122: 62-74.
98. Rosen V, (2006). BMP and BMP inhibitors in bone. Ann N Y Acad Sci 1068: 19-25.
99. Rosenzweig BL, Imamura T, Okadome T, Cox GN, Yamashita H, ten Dijke P, etal. (1995). Cloning and characterization of a human type II receptor for bone morphogenetic proteins. Proc Natl Acad Sci U S A 92: 7632-7636.
100. Roxburgh SA, Kattla JJ, Curran SP, O'Meara YM, Pollock CA, Goldschmeding R, etal. (2009). Allelic depletion of grem1 attenuates diabetic kidney disease. Diabetes 58: 1641-1650.
101. Sanvitale CE, Kerr G, Chaikuad A, Ramel MC, Mohedas AH, Reichert S, etal. (2013). A new class of small molecule inhibitor of BMP signaling. PLoS ONE 8: e62721.
102. Shen H, Huang GJ, Gong YW, (2003). Effect of transforming growth factor beta and bone morphogenetic proteins on rat hepatic stellate cell proliferation and trans-differentiation. World J Gastroenterol 9: 784-787.
103. Shi W, Sun C, He B, Xiong W, Shi X, Yao D, etal. (2004). GADD34-PP1c recruited by Smad7 dephosphorylates TGFbeta type I receptor. J Cell Biol 164: 291-300.
104. Shi W, Chang C, Nie S, Xie S, Wan M, Cao X, (2007). Endofin acts as a Smad anchor for receptor activation in BMP signaling. J Cell Sci 120 (Pt 7): 1216-1224.
105. Shi Y, Wang YF, Jayaraman L, Yang H, Massague J, Pavletich NP, (1998). Crystal structure of a Smad MH1 domain bound to DNA: insights on DNA binding in TGF-beta signaling. Cell 94: 585-594.
106. Soofi A, Zhang P, Dressler GR, (2013). Kielin/chordin-like protein attenuates both acute and chronic renal injury. J Am Soc Nephrol 24: 897-905.
107. Sotillo Rodriguez JE, Mansky KC, Jensen ED, Carlson AE, Schwarz T, Pham L, etal. (2009). Enhanced osteoclastogenesis causes osteopenia in twisted gastrulation-deficient mice through increased BMP signaling. J Bone Miner Res 24: 1917-1926.
108. Sugimoto H, Grahovac G, Zeisberg M, Kalluri R, (2007). Renal fibrosis and glomerulosclerosis in a new mouse model of diabetic nephropathy and its regression by bone morphogenic protein-7 and advanced glycation end product inhibitors. Diabetes 56: 1825-1833.
109. Sugimoto H, LeBleu VS, Bosukonda D, Keck P, Taduri G, Bechtel W, etal. (2012). Activin-like kinase 3 is important for kidney regeneration and reversal of fibrosis. Nat Med 18: 396-404.
110. Sugimoto H, LeBleu VS, Bosukonda D, Keck P, Taduri G, Bechtel W, etal. (2013). Reply to Regarding the mechanism of action of a proposed peptide agonist of the bone morphogenetic protein receptor activin-like kinase 3. Nat Med 19: 810-811.
111. Sun B, Huo R, Sheng Y, Li Y, Xie X, Chen C, etal. (2013). Bone morphogenetic protein-4 mediates cardiac hypertrophy, apoptosis, and fibrosis in experimentally pathological cardiac hypertrophy. Hypertension 61: 352-360.
112. Sun J, Zhuang FF, Mullersman JE, Chen H, Robertson EJ, Warburton D, etal. (2006). BMP4 activation and secretion are negatively regulated by an intracellular gremlin-BMP4 interaction. J Biol Chem 281: 29349-29356.
113. Suzuki A, Kaneko E, Maeda J, Ueno N, (1997). Mesoderm induction by BMP-4 and -7 heterodimers. Biochem Biophys Res Commun 232: 153-156.
114. Suzuki C, Murakami G, Fukuchi M, Shimanuki T, Shikauchi Y, Imamura T, etal. (2002). Smurf1 regulates the inhibitory activity of Smad7 by targeting Smad7 to the plasma membrane. J Biol Chem 277: 39919-39925.
115. Swiontkowski MF, Aro HT, Donell S, Esterhai JL, Goulet J, Jones A, etal. (2006). Recombinant human bone morphogenetic protein-2 in open tibial fractures. A subgroup analysis of data combined from two prospective randomized studies. J Bone Joint Surg Am 88: 1258-1265.
116. Tandon A, Sharma A, Rodier JT, Klibanov AM, Rieger FG, Mohan RR, (2013). BMP7 gene transfer via gold nanoparticles into stroma inhibits corneal fibrosis in vivo. PLoS ONE 8: e66434.
117. Tardif G, Pelletier JP, Boileau C, Martel-Pelletier J, (2009). The BMP antagonists follistatin and gremlin in normal and early osteoarthritic cartilage: an immunohistochemical study. Osteoarthritis Cartilage 17: 263-270.
118. Theriault BL, Shepherd TG, Mujoomdar ML, Nachtigal MW, (2007). BMP4 induces EMT and Rho GTPase activation in human ovarian cancer cells. Carcinogenesis 28: 1153-1162.
119. Tominaga T, Abe H, Ueda O, Goto C, Nakahara K, Murakami T, etal. (2011). Activation of bone morphogenetic protein 4 signaling leads to glomerulosclerosis that mimics diabetic nephropathy. J Biol Chem 286: 20109-20116.
120. Tsukazaki T, Chiang TA, Davison AF, Attisano L, Wrana JL, (1998). SARA, a FYVE domain protein that recruits Smad2 to the TGFbeta receptor. Cell 95: 779-791.
121. Urist MR, (1965). Bone: formation by autoinduction. Science 150: 893-899.
122. Vukicevic S, Basic V, Rogic D, Basic N, Shih MS, Shepard A, etal. (1998). Osteogenic protein-1 (bone morphogenetic protein-7) reduces severity of injury after ischemic acute renal failure in rat. J Clin Invest 102: 202-214.
123. Walsh DW, Roxburgh SA, McGettigan P, Berthier CC, Higgins DG, Kretzler M, etal. (2008). Co-regulation of gremlin and notch signalling in diabetic nephropathy. Biochim Biophys Acta 1782: 10-21.
124. Walsh DW, Godson C, Brazil DP, Martin F, (2010). Extracellular BMP-antagonist regulation in development and disease: tied up in knots. Trends Cell Biol 20: 244-256.
125. Wang S, Hirschberg R, (2003). BMP7 antagonizes TGF-beta-dependent fibrogenesis in mesangial cells. Am J Physiol Renal Physiol 284: F1006-F1013.
126. Wang S, Hirschberg R, (2004). Bone morphogenetic protein-7 signals opposing transforming growth factor beta in mesangial cells. J Biol Chem 279: 23200-23206.
127. Wang S, de Caestecker M, Kopp J, Mitu G, Lapage J, Hirschberg R, (2006). Renal bone morphogenetic protein-7 protects against diabetic nephropathy. J Am Soc Nephrol 17: 2504-2512.
128. Wang SN, Lapage J, Hirschberg R, (2001). Loss of tubular bone morphogenetic protein-7 in diabetic nephropathy. J Am Soc Nephrol 12: 2392-2399.
129. Weiskirchen R, Meurer SK, (2013). BMP-7 counteracting TGF-beta1 activities in organ fibrosis. Front Biosci 18: 1407-1434.
130. Whitman M, Rosen V, Brivanlou AH, Groppe JC, Sebald W, Mueller T, (2013). Regarding the mechanism of action of a proposed peptide agonist of the bone morphogenetic protein receptor activin-like kinase 3. Nat Med 19: 809-810.
131. Wilkinson L, Kolle G, Wen D, Piper M, Scott J, Little M, (2003). CRIM1 regulates the rate of processing and delivery of bone morphogenetic proteins to the cell surface. J Biol Chem 278: 34181-34188.
132. Wordinger RJ, Zode G, Clark AF, (2008). Focus on molecules: gremlin. Exp Eye Res 87: 78-79.
133. Wrana JL, (2000). Regulation of Smad activity. Cell 100: 189-192.
134. Wu XB, Li Y, Schneider A, Yu W, Rajendren G, Iqbal J, etal. (2003). Impaired osteoblastic differentiation, reduced bone formation, and severe osteoporosis in noggin-overexpressing mice. J Clin Invest 112: 924-934.
135. Xiao YT, Xiang LX, Shao JZ, (2007). Bone morphogenetic protein. Biochem Biophys Res Commun 362: 550-553.
136. Xu L, Chen YG, Massague J, (2000). The nuclear import function of Smad2 is masked by SARA and unmasked by TGFbeta-dependent phosphorylation. Nat Cell Biol 2: 559-562.
137. Xu T, Yu CY, Sun JJ, Liu Y, Wang XW, Pi LM, etal. (2011). Bone morphogenetic protein-4-induced epithelial-mesenchymal transition and invasiveness through Smad1-mediated signal pathway in squamous cell carcinoma of the head and neck. Arch Med Res 42: 128-137.
138. Yamada S, Nakamura J, Asada M, Takase M, Matsusaka T, Iguchi T, etal. (2014). Twisted gastrulation, a BMP antagonist, exacerbates podocyte injury. PLoS ONE 9: e89135.
139. Yan C, Grimm WA, Garner WL, Qin L, Travis T, Tan N, etal. (2010). Epithelial to mesenchymal transition in human skin wound healing is induced by tumor necrosis factor-alpha through bone morphogenic protein-2. Am J Pathol 176: 2247-2258.
140. Yang T, Chen SL, Lu XJ, Shen CY, Liu Y, Chen YP, (2012). Bone morphogenetic protein 7 suppresses the progression of hepatic fibrosis and regulates the expression of gremlin and transforming growth factor beta1. Mol Med Rep 6: 246-252.
141. Yang YL, Liu YS, Chuang LY, Guh JY, Lee TC, Liao TN, etal. (2009). Bone morphogenetic protein-2 antagonizes renal interstitial fibrosis by promoting catabolism of type I transforming growth factor-beta receptors. Endocrinology 150: 727-740.
142. Yang YL, Ju HZ, Liu SF, Lee TC, Shih YW, Chuang LY, etal. (2011). BMP-2 suppresses renal interstitial fibrosis by regulating epithelial-mesenchymal transition. J Cell Biochem 112: 2558-2565.
143. Yoshida Y, Tanaka S, Umemori H, Minowa O, Usui M, Ikematsu N, etal. (2000). Negative regulation of BMP/Smad signaling by Tob in osteoblasts. Cell 103: 1085-1097.
144. Yu PB, Deng DY, Lai CS, Hong CC, Cuny GD, Bouxsein ML, etal. (2008a). BMP type I receptor inhibition reduces heterotopic [corrected] ossification. Nat Med 14: 1363-1369.
145. Yu PB, Hong CC, Sachidanandan C, Babitt JL, Deng DY, Hoyng SA, etal. (2008b). Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism. Nat Chem Biol 4: 33-41.
146. Yuan S, Pan Q, Liu W, Wu B, Han X, Bi Z, (2011). Recombinant BMP 4/7 fusion protein induces differentiation of bone marrow stem cells. J Cell Biochem 112: 3054-3060.
147. Zawel L, Dai JL, Buckhaults P, Zhou S, Kinzler KW, Vogelstein B, etal. (1998). Human Smad3 and Smad4 are sequence-specific transcription activators. Mol Cell 1: 611-617.
148. Zeisberg EM, Tarnavski O, Zeisberg M, Dorfman AL, McMullen JR, Gustafsson E, etal. (2007). Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med 13: 952-961.
149. Zeisberg M, Bottiglio C, Kumar N, Maeshima Y, Strutz F, Muller GA, etal. (2003a). Bone morphogenic protein-7 inhibits progression of chronic renal fibrosis associated with two genetic mouse models. Am J Physiol Renal Physiol 285: F1060-F1067.
150. Zeisberg M, Hanai J, Sugimoto H, Mammoto T, Charytan D, Strutz F, etal. (2003b). BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med 9: 964-968.
151. Zeisberg M, Shah AA, Kalluri R, (2005). Bone morphogenic protein-7 induces mesenchymal to epithelial transition in adult renal fibroblasts and facilitates regeneration of injured kidney. J Biol Chem 280: 8094-8100.
152. Zhang F, Qiu T, Wu X, Wan C, Shi W, Wang Y, etal. (2009). Sustained BMP signaling in osteoblasts stimulates bone formation by promoting angiogenesis and osteoblast differentiation. J Bone Miner Res 24: 1224-1233.
153. Zhang Q, Shi Y, Wada J, Malakauskas SM, Liu M, Ren Y, etal. (2010). In vivo delivery of gremlin siRNA plasmid reveals therapeutic potential against diabetic nephropathy by recovering bone morphogenetic protein-7. PLoS ONE 5: e11709.
154. Zhong L, Wang X, Wang S, Yang L, Gao H, Yang C, (2013). The anti-fibrotic effect of bone morphogenic protein-7(BMP-7) on liver fibrosis. Int J Med Sci 10: 441-450.
155. Zhu H, Kavsak P, Abdollah S, Wrana JL, Thomsen GH, (1999). A SMAD ubiquitin ligase targets the BMP pathway and affects embryonic pattern formation. Nature 400: 687-693.
156. Zhu W, Kim J, Cheng C, Rawlins BA, Boachie-Adjei O, Crystal RG, etal. (2006). Noggin regulation of bone morphogenetic protein (BMP) 2/7 heterodimer activity in vitro. Bone 39: 61-71.
157. Zimmerman LB, De Jesus-Escobar JM, Harland RM, (1996). The Spemann organizer signal noggin binds and inactivates bone morphogenetic protein 4. Cell 86: 599-606.
158. Ziran BH, Hendi P, Smith WR, Westerheide K, Agudelo JF, (2007). Osseous healing with a composite of allograft and demineralized bone matrix: adverse effects of smoking. Am J Orthop 36: 207-209.